2. Search Result
Search Result
Results for "

kidney cancer

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

1

Screening Libraries

3

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-157395
    malonyl-NAC

    		Others Cancer
    malonyl-NAC increases cellular propylation, resulting in reduced endogenous GAPDH activity. malonyl-NAC increases GAPDH malonylation in cells and inhibits pyruvate kinase activity. In addition, malonyl-NAC limits the metabolism and proliferation of a highly glycolytic kidney cancer cell line harboring a tricarboxylic acid cycle mutation .
    malonyl-NAC
  • HY-N0164
    Matrine
    Maximum Cited Publications
    12 Publications Verification

    Matridin-15-one; Vegard; α-Matrine

    		 PINK1/Parkin Opioid Receptor Autophagy Mitophagy Ferroptosis Apoptosis Inflammation/Immunology Cancer
    Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI) .
    Matrine
  • HY-150076
    BLU2864

    		Others Metabolic Disease Cancer
    BLU2864 is an orally active, highly selective, ATP-competitive PRKACA inhibitor (IC50=0.3 nM). BLU2864 shows anti-tumor activity. BLU2864 can be used in cancer and polycystic kidney disease research .
    BLU2864
  • HY-155249
    KGP591

    		Microtubule/Tubulin Cancer
    KGP591 is a tubulin polymerization inhibitor (IC50 0.57 µM). KGP591 induces significant G2/M stagnation, inhibits cell migration, disrupts microtubule structure and cell morphology in MDA-MB-231 cells. KGP591 shows antitumor activity in orthotopic model of kidney cancer (RENCA) .
    KGP591
  • HY-147971
    Anticancer agent 75

    		Parasite Topoisomerase Infection Cancer
    Anticancer agent 75 is a potent anticancer agent. Anticancer agent 75 shows cytotoxicity and selectivity in cancer cell lines. Anticancer agent 75 shows cytotoxicity to normal human kidney cell lines is at least 35 times lower than that of the Doxorubicin standard. Anticancer agent 75 shows good activity of antiplasmodial .
    Anticancer agent 75
  • HY-143546
    RET-IN-9

    		RET Cancer
    RET-IN-9 is a potent inhibitor of RET. RET kinase is a single-pass transmembrane receptor tyrosine kinase that plays an important role in the development of the kidney and enteric nervous system, and the maintenance of homeostasis in the nervous, endocrine, hematopoietic, and male reproductive systems. RET-IN-9 has the potential for the research of RET-related disease including non-small cell lung cancer and medullary thyroid cancer (extracted from patent WO2021115457A1, compound 29) .
    RET-IN-9
  • HY-144425
    BSc5367

    		Others Inflammation/Immunology
    BSc5367 is a potent Nek1 inhibitor with an IC50 of 11.5 nM. NIMA-related protein kinase Nek1 is crucially involved in cell cycle regulation, DNA repair and microtubule regulation and dysfunctions of Nek1 play key roles in amyotrophic lateral sclerosis (ALS), polycystic kidney disease (PKD) and several types of radiotherapy resistant cancer .
    BSc5367
  • HY-152479
    Topoisomerase IIα-IN-7

    		Topoisomerase Cancer
    Topoisomerase IIα-IN-7 is an DNA topoisomerase IIα inhibitor with an IC50 value of 7.7 µM. Topoisomerase IIα-IN-7 has broad-spectrum cytotoxicity to leukemia, lung, colon, melanoma, ovarian, kidney, prostate and breast cancer cells. Topoisomerase IIα-IN-7 has metabolic stability .
    Topoisomerase IIα-IN-7
  • HY-156527
    PHD-IN-2

    		HIF/HIF Prolyl-Hydroxylase Cancer
    PHD-IN-2 (Compound 91) is a PHD antagonist (IC50: < 5 nM). PHD-IN-2 induces erythropoietin synthesis in HEP3B cells (EC50: <2.5 μM). PHD-IN-2 can be used for research of cardiovascular disorders, metabolic disorders, hematological disorders, pulmonary disorders, kidney disorders, liver disorders, wound healing disorders, and cancer .
    PHD-IN-2
  • HY-163074
    Ferroptosis-IN-6

    		Ferroptosis Cancer
    Ferroptosis-IN-6 (compound 13) is a potent inhibitor of Ferroptosis with EC50 of 25.5 nM. Ferroptosis-IN-6 significantly inhibits RSL3-induced cell death in cells and in vivo .
    Ferroptosis-IN-6
  • HY-144332
    PHD2/HDACs-IN-1

    		HDAC HIF/HIF Prolyl-Hydroxylase Cancer
    PHD2/HDACs-IN-1 is a potent PHD2/HDACs hybrid inhibitor (IC50s of 1.15 μM, 19.75 μM, 26.60 μM and 15.98 μM for PHD2, HDAC1, HDAC2 and HDAC6, respectively). PHD2/HDACs-IN-1 is a low-toxicity renoprotective agent for research of cisplatin-induced acute kidney injury (AKI) .
    PHD2/HDACs-IN-1
  • HY-B1357
    Digitoxin
    3 Publications Verification

    		 Bcl-2 Family Caspase Apoptosis HSV Na+/K+ ATPase Calcium Channel Cardiovascular Disease Cancer
    Digitoxin is an anti-cancer agent. Digitoxin induces apoptosis, inhibits influenza cytokine storm, causes DNA double-stranded breaks (DSBs) and blocks the cell cycle at the G2/M phase. Digitoxin induces calcium uptake into cells by forming transmembrane calcium channels and can be used for research of heart failure .
    Digitoxin
  • HY-125108
    PHPS1 sodium

    		SHP2 Phosphatase Cardiovascular Disease Cancer
    PHPS1 sodium is a potent and selective Shp2 inhibitor with Kis of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively .
    PHPS1 sodium
  • HY-112368
    PHPS1

    		SHP2 Phosphatase Cardiovascular Disease Cancer
    PHPS1 is a potent and selective Shp2 inhibitor with Kis of 0.73, 5.8, 10.7, 5.8, and 0.47 μM for Shp2, Shp2-R362K, Shp1, PTP1B, and PTP1B-Q, respectively .
    PHPS1
  • HY-137605
    WSF1-IN-1

    		Others Cancer
    WSF1-IN-1 (compound 136), an orally active WSF1 inhibitor, can be used in the study for WSF1 (Wolfram syndrome) related tumors, with IC50 values of 0.33 μM and >27 μM in HepG2 parental and HepG2 WFS1 KO cell lines, respectively .
    WSF1-IN-1
  • HY-136379
    CID44216842
    1 Publications Verification

    Cdc42-IN-1

    		 Ras Cancer
    CID44216842 (Cdc42-IN-1) is a potent Cdc42-selective guanine nucleotide binding lead inhibitor. The EC50s for Cdc42 WT and Cdc42Q61L mutant are 1.0 and 1.2 μM in GTP binding assay, respectively. The EC50s for Cdc42 WT and Cdc42Q61L mutant are 0.3 and 0.5 μM in GDP binding assay, respectively. Use as a molecular probe .
    CID44216842
  • HY-Y0966
    Glycine
    4 Publications Verification

    		 Endogenous Metabolite iGluR VEGFR Neurological Disease
    Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis .
    Glycine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: